Prospective Study of Patients With Thrombocytopenia Following HSCT
Status:
Completed
Trial end date:
2019-04-12
Target enrollment:
Participant gender:
Summary
Isolated thrombocytopenia is a common and severe complication of HSCT, which often leads to
an increased risk of life-threatening hemorrhage, frequent requirement of platelet
transfusions and extended hospital stays, representing a challenging clinical problem.
Current treatments for thrombocytopenia after HSCT are frequently unsatisfactory in platelet
recovery and for preventing potentially fatal bleeding complications. Therefore, it is urgent
to explore an effective therapy to improve the outcomes of thrombocytopenia after HSCT.
Previous studies have demonstrated that decitabine, a hypomethylating agent, may reduce
platelet transfusions in myelodysplastic syndrome (MDS) patients. The investigators conducted
an prospective clinical trial to evaluate the safety and efficiency of rhTPO and decitabine
in the treatment of thrombocytopenia following HSCT.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Children's Hospital Of Soochow University Fujian Medical University Union Hospital Hebei Yanda Ludaopei Hospital Nanfang Hospital of Southern Medical University Peking University People's Hospital Qilu Hospital of Shandong University Ruijin Hospital Wuhan Union Hospital, China